Study on the performance measurement and comparison of China's pharmaceutical industry based on big data analysis

In the past, enterprises used to judge their performance based on a single indicator. But in the information age, big data is essential for measuring enterprise performance. This paper takes the listed pharmaceutical industry as the research object, and measures and compares the performance of China's pharmaceutical industry from both dynamic and static aspects through big data analysis. The study found that between 2013 and 2022, the average performance of China's pharmaceutical industry showed a U-shaped trend. The main reason is that the innovation ability of the pharmaceutical industry is declining, while the scale efficiency is continuously improving. At the same time, the performance of the pharmaceutical industry varies in terms of enterprise scale, nature of property rights, region, product categories. Therefore, this paper suggests that China's pharmaceutical industry should increase R&D investment, and expanding production scale while enhancing resource allocation to achieve high-quality development in China's pharmaceutical industry.